Abstract
BackgroundNon-small cell lung cancer (NSCLC) is a deadly human malignancy, and previous studies support the contribution of microRNAs (miRNAs) to cancer assessment. It has been reported that miR-1231 can be used as a biomarker to assess prognosis in different cancers. However, the prognostic value of miR-1231 in NSCLC patients with comorbid diabetes mellitus (DM) remains unclear. The present study evaluated the risk factors for NSCLC with DM and developed a predictive model for it.MethodsA real-world study was conducted, including data from 108 patients with NSCLC combined with DM from April 1, 2010, to June 1, 2015. MiR-1231 was recorded during hospital admission. Cox-proportional hazards model was applied for survival analysis of risk factors for cancer-related mortality and to create nomograms for prediction. The accuracy of the model was evaluated by C-index and calibration curves.ResultsThe mortality rate in the high miR-1231 level (≥ 1.775) group was 57.4%. On the basis of univariate analysis, we put factors (P < 0.05) into multivariate regression models, and high miR-1231 levels (P < 0.001, HR = 0.57), surgery (P < 0.001, HR = 0.37) and KPS score > 80 (P = 0.01, HR = 0.47) had a better prognosis and were considered as independent protective factors. These independently relevant factors were used to create nomograms to predict long-term patient survival. Nomogram showed good accuracy in risk estimation with a guide-corrected C-index of 0.691.ConclusionMiR-1231 reduced the risk of cancer-related death in patients with combined NSCLC and DM. Nomogram based on multivariate analysis showed good accuracy in estimating the overall risk of death.
Highlights
Non-small cell lung cancer (NSCLC) is a deadly human malignancy, and previous studies support the contribution of microRNAs to cancer assessment
Lung cancer is divided by pathology into small cell lung cancer and non-small cell lung cancer (NSCLC), which account for 15% and 85% of lung cancer cases, respectively [2]
For the stage of NSCLC, 17 (16.0%) patients were diagnosed with stage I, 8 (7.0%) with stage II, 20 (19.0%) with stage III, and 63 (58.0%) with stage IV. (40.0%) patients underwent surgery. (43.0%) patients underwent radiation therapy
Summary
Non-small cell lung cancer (NSCLC) is a deadly human malignancy, and previous studies support the contribution of microRNAs (miRNAs) to cancer assessment. It has been reported that miR-1231 can be used as a biomarker to assess prognosis in different cancers. MicroRNAs (miRNAs) are a group of highly conserved non-coding RNAs (ncRNAs) that are 20-24 nucleotides in length [5]. Many evidence suggests that aberrant expression and regulation of miRNAs play an essential role in the development of human cancers. Some miRNAs can affect many types of malignancies and serve as biomarkers for these cancers [8]. Several miRNAs have been shown to play an essential role in the development of NSCLC, but few are likely to be biomarkers or candidates for targeted therapies
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
